You’re reading Entrepreneur United States, an international franchise of Entrepreneur Media.
This story originally appeared on Zacks
Momentum investors typically don’t time the market or „buy low and sell high.“ In other words, they avoid betting on cheap stocks and waiting long for them to recover. Instead, they believe that „buying high and selling higher“ is the way to make far more money in lesser time.
Who doesn’t like betting on fast-moving trending stocks? But determining the right entry point isn’t easy. Often, these stocks lose momentum once their valuation moves ahead of their future growth potential. In such a situation, investors find themselves loaded up on expensive shares with limited to no upside or even a downside. So, going all-in on momentum could be risky at times.
A safer approach could be investing in bargain stocks with recent price momentum. While the Zacks Momentum Style Score (part of the Zacks Style Scores system) helps identify great momentum stocks by paying close attention to trends in a stock’s price or earnings, our ‚Fast-Paced Momentum at a Bargain‘ screen comes handy in spotting fast-moving stocks that are still attractively priced.
There are several stocks that currently pass through the screen and Endo International (ENDP) is one of them. Here are the key reasons why this stock is a great candidate.
Investors‘ growing interest in a stock is reflected in its recent price increase. A price change of 44.4% over the past four weeks positions the stock of this health care company well in this regard.
While any stock can see a spike in price for a short period, it takes a real momentum player to deliver positive returns for a longer time frame. ENDP meets this criterion too, as the stock gained 188.1% over the past 12 weeks.
Moreover, the momentum for ENDP is fast paced, as the stock currently has a beta of 1.21. This indicates that the stock moves 21% higher than the market in either direction.
Given this price performance, it is no surprise that ENDP has a Momentum Score of B, which indicates that this is the right time to enter the stock to take advantage of the momentum with the highest probability of success.
In addition to a favorable Momentum Score, an upward trend in earnings estimate revisions has helped ENDP earn a Zacks Rank #1 (Strong Buy). Our research shows that the momentum-effect is quite strong among Zacks Rank #1 and #2 stocks. That’s because as covering analysts raise their earnings estimates for a stock, more and more investors take an interest in it, helping its price race to keep up. You can see the complete list of today’s Zacks Rank #1 (Strong Buy) stocks here >>>>
Most importantly, despite possessing fast-paced momentum features, ENDP is trading at a reasonable valuation. In terms of Price-to-Sales ratio, which is considered as one of the best valuation metrics, the stock looks quite cheap now. ENDP is currently trading at 0.48 times its sales. In other words, investors need to pay only 48 cents for each dollar of sales.
So, ENDP appears to have plenty of room to run, and that too at a fast pace.
In addition to ENDP, there are several other stocks that currently pass through our ‚Fast-Paced Momentum at a Bargain‘ screen. You may consider investing in them and start looking for the newest stocks that fit these criteria.
This is not the only screen that could help you find your next winning stock pick. Based on your personal investing style, you may choose from over 45 Zacks Premium Screens that are strategically created to beat the market.
However, keep in mind that the key to a successful stock-picking strategy is to ensure that it produced profitable results in the past. You could easily do that with the help of the Zacks Research Wizard. In addition to allowing you to backtest the effectiveness of your strategy, the program comes loaded with some of our most successful stock-picking strategies.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Endo International plc (ENDP): Free Stock Analysis Report
To read this article on Zacks.com click here.